|
English
|
正體中文
|
简体中文
|
总笔数 :2853524
|
|
造访人次 :
45207941
在线人数 :
691
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"楊志新"的相关文件
显示项目 131-140 / 209 (共21页)
<< < 9 10 11 12 13 14 15 16 17 18 > >>
每页显示[10|25|50]项目
| 國立臺灣大學 |
2009 |
First-Line Systemic Treatment of Advanced Stage Non-Small-Cell Lung Cancer in Asia: Consensus Statement from the Asian Oncology Summit 2009
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Comparison of Epidermal Growth Factor Receptor Mutations between Primary and Corresponding Metastatic Tumors in Tyrosine Kinase Inhibitor-Naive Non -Small-Cell Lung Cancer
|
高劍虹; 張逸良; 蔡孟峰; 吳振都; 余忠仁; 楊志新; 李元麒; 楊泮池; 施金元; GOW, CHIEN-HUNG; CHANG, YIH-LEONG; TSAI, MENG-FENG; WU, CHEN-TU; YU, CHONG-JEN; YANG, CHIH-HSIN; LEE, YUNG-CHIE; YANG, PAN-CHYR; SHIH, JIN-YUAN |
| 國立臺灣大學 |
2009 |
Egfr Intron 1 Dinucleotide Repeat Polymorphism Is Associated with the Occurrence of Skin Rash with Gefitinib Treatment
|
黃敬倫; 楊志新; 葉坤輝; 胡賦强; 陳冠宇; 施金元; 林宗哲; 余忠仁; 鄭安理; 楊泮池; HUANG, CHING-LUN; YANG, CHIH-HSIN; YEH, KUN-HUEI; HU, FU-CHANG; CHEN, KUAN-YU; SHIH, JIN-YUAN; LIN, ZONG-ZHE; YU, CHONG-JEN; CHENG, ANN-LII; YANG, PAN-CHYR |
| 國立臺灣大學 |
2009 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer
|
林家齊; 楊志新; LIN, CHIA-CHI; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
林家齊; 楊志新; 鄭安理; 陳榮楷; 何弘能; LIN, CHIA-CHI; YANG, CHIH-HSIN; CHENG, ANN-LII; CHAN, WING-KAI; HO, HONG-NERNG |
| 國立臺灣大學 |
2009 |
Quality of Life in Advanced Non-Small Cell Lung Cancer Patients Receiving First-Line Gefitinib Monotherapy
|
邵幼雲; 林宗哲; 胡賦强; 余忠仁; 施金元; 胡文郁; 張逸良; 鄭安理; 楊泮池; 楊志新; SHAO, YU-YUN; LIN, ZONG-ZHE; HU, FU-CHANG; YU, CHONG-JEN; SHIH, JIN-YUAN; HU, WEN-YU; CHANG, YIH-LEONG; CHENG, ANN-LII; YANG, PAN-CHYR; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Bibw 2992, a Novel Irreversible Dual Egfr and Her2 Tyrosine Kinase Inhibitor (Tki), in Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations after Failure of One Line of Chemotherapy (Lux-Lung 2)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Biomarker Analyses from a Phase Iii, Randomized, Open-Label, First-Line Study of Gefitinib (G) Versus Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) in Asia (Ipass)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Efficacy of Pemetrexed-Cisplatin (Pc) in East Asian Patients (Pts): Subgroup Analysis of a Phase Iii Study Comparing Pc Versus Gemcitabine- Cisplatin (Gc) in First-Line Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc)
|
楊志新; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2009 |
Phase Iib/Iii Double-Blind Randomized Trial of Bibw 2992, an Irreversible, Dual Inhibitor of Egfr and Her2 Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc in Patients with Nsclc Failing 1-2 Lines of Chemotherapy (Ct) and Erlotinib or Gefitinib (Lu
|
楊志新; YANG, CHIH-HSIN |
显示项目 131-140 / 209 (共21页)
<< < 9 10 11 12 13 14 15 16 17 18 > >>
每页显示[10|25|50]项目
|
